Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

A Plasma-Based Assay to Measure the Susceptibility of Factor V(a) to Inhibition By TFPIα

Tilman M. Hackeng, PhD, Peter van Doorn, MSc, Jan Rosing, PhD, Joost Meijers, PhD, Saskia Middeldorp, MD PhD, Paolo Simioni, MD PhD, Elisabetta Castoldi, PhD

Blood (2018) 132 (Supplement 1): 1168.

https://doi.org/10.1182/blood-2018-99-118767

Published: 2018

Journal Articles

New Functional Assays to Selectively Quantify APC- and TFPI-Cofactor Activities of Protein S in Plasma

Nahla Alshaikh, Msc, Jan Rosing, PhD, Stella Thomassen, Elisabetta Castoldi, PhD, Paolo Simioni, MD PhD, Tilman M. Hackeng, PhD

Blood (2016) 128 (22): 717.

https://doi.org/10.1182/blood.V128.22.717.717

Published: 2016

Journal Articles

The C-Terminus of Tfpiα Inhibits Factor V Activation By Protecting the Arg 1545 Cleavage Site

Peter van Doorn, Msc, Jan Rosing, PhD, Simone Wielders, Tilman M. Hackeng, PhD, Elisabetta Castoldi, PhD

Blood (2016) 128 (22): 257.

https://doi.org/10.1182/blood.V128.22.257.257

Published: 2016

Journal Articles

Fibrinogen γ′ increases the sensitivity to activated protein C in normal and factor V Leiden plasma

Farida Omarova, Shirley Uitte de Willige, Paolo Simioni, Robert A. S. Ariëns, Rogier M. Bertina, Jan Rosing, Elisabetta Castoldi

Blood (2014) 124 (9): 1531–1538.

https://doi.org/10.1182/blood-2014-02-554055

Published: 2014

Journal Articles

TFPI Expresses Anticoagulant Activity Independent Of TF-FVIIa

Stella Thomassen, PhD, Alexandra Heinzmann, PhD, Linda Herfs, Jan Rosing, PhD, Tilman M. Hackeng, PhD, Rudolf Hartmann, PhD, Friedrich Scheiflinger, PhD, Michael Dockal, PhD

Blood (2013) 122 (21): 3563.

https://doi.org/10.1182/blood.V122.21.3563.3563

Published: 2013

Journal Articles

Design Of a Most Efficient Inhibitor Of TFPI By Molecular Fusion Of Two Inhibitory Peptides

Michael Dockal, PhD, Rudolf Hartmann, PhD, Thomas Polakowski, PhD, Johannes Brandstetter, PhD, Willibald Kammlander, Erwin Panholzer, Christoph Redl, Frank Osterkamp, PhD, Jan Rosing, PhD, Friedrich Scheiflinger, PhD

Blood (2013) 122 (21): 3564.

https://doi.org/10.1182/blood.V122.21.3564.3564

Published: 2013

Journal Articles

Crystal Structure Of Tissue Factor Pathway Inhibitor (TFPI) Kunitz Domain 1 and 2 In Complex With An Inhibitory Cyclic Peptide,

Michael Dockal, PhD, Rudolf Hartmann, PhD, Markus Fries, PhD, Katerina Prohaska, Robert Pachlinger, PhD, Thomas Polakowski, PhD, Johannes Brandstetter, PhD, Jan Rosing, PhD, Friedrich Scheiflinger, PhD

Blood (2013) 122 (21): 453.

https://doi.org/10.1182/blood.V122.21.453.453

Published: 2013

Journal Articles

Peptides Binding to Kunitz Domain 1 of Tissue Factor Pathway Inhibitor (TFPI) Inhibit All Functions of TFPI and Improve Thrombin Generation of Hemophilia Plasma

Michael Dockal, PhD, Johannes Brandstetter, PhD, Martin Ludwiczek, Georg Kontaxis, PhD, Markus Fries, PhD, M C L G D Thomassen, PhD, A Heinzmann, PhD, Hartmut J. Ehrlich, MD, Katerina Prohaska, Rudolf Hartmann, PhD, Jan Rosing, Professor, Friedrich Scheiflinger, PhD

Blood (2011) 118 (21): 2245.

https://doi.org/10.1182/blood.V118.21.2245.2245

Published: 2011

Journal Articles

High Thrombin Generation Measured In the Presence of Activated Protein C Is Associated with An Increased Risk of Recurrence Among Women 18–64 Years After a First Event of VTE

Kristina Sonnevi, MD, Svetlana N Tchaikovski, MD, PhD, Katarina Bremme, MD, PhD, Margareta Holmstrom, MD, PhD, Jan Rosing, Professor, Gerd Larfars, MD, PhD

Blood (2010) 116 (21): 154.

https://doi.org/10.1182/blood.V116.21.154.154

Published: 2010

Journal Articles

Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms

Connie Duckers, Paolo Simioni, Luca Spiezia, Claudia Radu, Paolo Dabrilli, Sabrina Gavasso, Jan Rosing, Elisabetta Castoldi

Blood (2010) 115 (4): 879–886.

https://doi.org/10.1182/blood-2009-08-237719

Published: 2010

Journal Articles

Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera

Marina Marchetti, Elisabetta Castoldi, Henri M. H. Spronk, René van Oerle, Donatella Balducci, Tiziano Barbui, Jan Rosing, Hugo ten Cate, Anna Falanga

Blood (2008) 112 (10): 4061–4068.

https://doi.org/10.1182/blood-2008-06-164087

Published: 2008

Journal Articles

Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency

Connie Duckers, Paolo Simioni, Luca Spiezia, Claudia Radu, Sabrina Gavasso, Jan Rosing, Elisabetta Castoldi

Blood (2008) 112 (9): 3615–3623.

https://doi.org/10.1182/blood-2008-06-162453

Published: 2008

Journal Articles

Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation

Lisbeth F. A. Maurissen, M. Christella L. G. D. Thomassen, Gerry A. F. Nicolaes, Björn Dahlbäck, Guido Tans, Jan Rosing, Tilman M. Hackeng

Blood (2008) 111 (6): 3034–3041.

https://doi.org/10.1182/blood-2007-06-089987

Published: 2008

Journal Articles

An underestimated combination of opposites resulting in enhanced thrombotic tendency

Paolo Simioni, Elisabetta Castoldi, Barbara Lunghi, Daniela Tormene, Jan Rosing, Francesco Bernardi

Blood (2005) 106 (7): 2363–2365.

https://doi.org/10.1182/blood-2005-04-1461

Published: 2005

Journal Articles

Inhibition of thrombin generation by protein S at low procoagulant stimuli: implications for maintenance of the hemostatic balance

Kristin M. Seré, Jan Rosing, Tilman M. Hackeng

Blood (2004) 104 (12): 3624–3630.

https://doi.org/10.1182/blood-2004-03-1146

Published: 2004

Journal Articles

Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations

Elisabetta Castoldi, Jeroen M. Brugge, Gerry A. F. Nicolaes, Domenico Girelli, Guido Tans, Jan Rosing

Blood (2004) 103 (11): 4173–4179.

https://doi.org/10.1182/blood-2003-10-3578

Published: 2004

Journal Articles

Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial

Jeanet M. Kemmeren, Ale Algra, Joost C. M. Meijers, Guido Tans, Bonno N. Bouma, Joyce Curvers, Jan Rosing, Diederick E. Grobbee

Blood (2004) 103 (3): 927–933.

https://doi.org/10.1182/blood-2003-04-1285

Published: 2004

Includes: Supplemental data

Journal Articles

Coinheritance of Factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation

Elisabetta Castoldi, José W. P. Govers-Riemslag, Mirko Pinotti, Debora Bindini, Guido Tans, Mauro Berrettini, Maria Gabriella Mazzucconi, Francesco Bernardi, Jan Rosing

Blood (2003) 102 (12): 4014–4020.

https://doi.org/10.1182/blood-2003-04-1199

Published: 2003

Journal Articles

The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation

Rory R. Koenen, Guido Tans, René van Oerle, Karly Hamulyák, Jan Rosing, Tilman M. Hackeng

Blood (2003) 102 (5): 1686–1692.

https://doi.org/10.1182/blood-2003-02-0620

Published: 2003

NARROW

A Plasma-Based Assay to Measure the Susceptibility of Factor V(a) to Inhibition By TFPIα

New Functional Assays to Selectively Quantify APC- and TFPI-Cofactor Activities of Protein S in Plasma

The C-Terminus of Tfpiα Inhibits Factor V Activation By Protecting the Arg 1545 Cleavage Site

Fibrinogen γ′ increases the sensitivity to activated protein C in normal and factor V Leiden plasma

TFPI Expresses Anticoagulant Activity Independent Of TF-FVIIa

Design Of a Most Efficient Inhibitor Of TFPI By Molecular Fusion Of Two Inhibitory Peptides

Crystal Structure Of Tissue Factor Pathway Inhibitor (TFPI) Kunitz Domain 1 and 2 In Complex With An Inhibitory Cyclic Peptide,

Peptides Binding to Kunitz Domain 1 of Tissue Factor Pathway Inhibitor (TFPI) Inhibit All Functions of TFPI and Improve Thrombin Generation of Hemophilia Plasma

High Thrombin Generation Measured In the Presence of Activated Protein C Is Associated with An Increased Risk of Recurrence Among Women 18–64 Years After a First Event of VTE

Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms

Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera

Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency

Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation

An underestimated combination of opposites resulting in enhanced thrombotic tendency

Inhibition of thrombin generation by protein S at low procoagulant stimuli: implications for maintenance of the hemostatic balance

Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations

Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial

Coinheritance of Factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation

The APC-independent anticoagulant activity of protein S in plasma is decreased by elevated prothrombin levels due to the prothrombin G20210A mutation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only